drugset / Trial / NCT00357721

Atazanavir Twice Daily

NCT00357721

Phase 1 Completed 18 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-label

Summary

The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir administered twice-daily relative to historical data from atazanavir/ritonavir 300/100 mg, given once daily.

Timeline

Start
2006-06
Primary completion
2006-09
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atazanavir Other / unclassified 200 mg Oral
Comparator Atazanavir Other / unclassified 300 mg Oral
Comparator Atazanavir Other / unclassified 400 mg Oral